跳至主要内容
临床试验/NCT01357941
NCT01357941Unknown不适用

Prospective Study Assessing the Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism

Hamilton Health Sciences Corporation2 个研究点 分布在 1 个国家目标入组 203 人开始时间: 2011年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
203
试验地点
2
主要终点
Symptomatic venous thromboembolism

研究概览

简要总结

Pregnant women with a prior history of venous thromboembolism (VTE) are at increased risk of recurrent VTE. Current guidelines assessing the role of prophylaxis in pregnant women with prior VTE are based primarily on expert opinion and the optimal clinical management strategy remains unclear.

This multicentre, prospective cohort study aims to test the following hypotheses:

  1. Antepartum prophylaxis with fixed-dose low molecular-weight heparin (LMWH) is safe, convenient and associated with an acceptably low risk of recurrent VTE in women with a single prior episode of VTE that was either unprovoked or associated with a minor transient risk factor. (Moderate risk cohort)
  2. Withholding antepartum prophylaxis is safe (recurrence risk <1%) in pregnant women with a single prior episode of VTE provoked by a major transient risk factor. (Low risk cohort)

All study patients will receive 6 weeks of postpartum prophylaxis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Confirmed pregnancy (positive serum or urine)
  • At least 18 years of age
  • History of one prior episode of VTE consisting of DVT (diagnosed by compression ultrasonography [CUS] or venography) and/or PE (diagnosed by ventilation-perfusion [V/Q] lung scintigraphy, computed tomographic pulmonary angiography [CTPA], or traditional pulmonary angiography)

排除标准

  • Ongoing need for therapeutic anticoagulation for prevention or treatment of cardioembolic stroke
  • Known high-risk thrombophilia (specifically antithrombin deficiency, protein S deficiency, protein C deficiency, homozygosity for the factor V Leiden or prothrombin G20210A mutations, antiphospholipid antibody or compound abnormalities)
  • VTE within 3 months of the current pregnancy
  • Clinical risk factor for initial episode of VTE, if present, not resolved (excluding pregnancy)
  • Known contraindication to anticoagulation (including active, uncontrolled bleeding or major bleed within the previous 4 weeks)
  • For patients with prior unprovoked VTE, contraindication to LMWH (including allergy, HIT, impaired renal function, osteoporosis)
  • Geographic or social factors precluding follow-up
  • Inability or unwillingness to provide informed consent

结局指标

主要结局

Symptomatic venous thromboembolism

时间窗: antepartum period (expected average 7 months)

Symptomatic objectively confirmed recurrent VTE, including proximal DVT, non-fatal PE, and fatal PE during antepartum period

次要结局

  • Symptomatic recurrent venous thromboembolism(antepartum period (expected average 7 months) and first 3 months postpartum)
  • Symptomatic recurrent pulmonary embolism(antepartum period (expected average 7 months) and first 3 months postpartum)
  • Thrombocytopenia or heparin-induced thrombocytopenia (HIT)(antepartum period (expected average 7 months))
  • Symptomatic osteoporosis(antepartum period (expected average 7 months) and first 3 months postpartum)
  • Other complications(antepartum (expected average 7 months) and within first 3 months postpartum)
  • Pregnancy complications and outcomes(antepartum period (expected average 7 months))
  • Fetal anomalies(antepartum (expected average 7 months) and during first 3 months postpartum)
  • Major and minor bleeding(antepartum (expected average 7 months))

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验